Skip to main content
REMEVi
ENES
What REMEVi offers

BPC-157 side effects: human, animal and unknown

What has been reported, what has not been studied, and how to report a reaction.

Little is known about BPC-157 side effects in people. Animal studies report few adverse effects, but human data are limited to a few small reports, and FDA says it lacks sufficient information to know whether BPC-157 would cause harm in humans. Injection-site reactions are possible with any injection. No one can call it risk-free.

BPC-157 is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.

REMEVi does not currently offer BPC-157.

Reported in human studies

A 2025 systematic review found no clinical safety data on BPC-157 in humans. The few human reports are small and uncontrolled:

  • A 2025 pilot gave intravenous BPC-157 to two adults over two days and reported no side effects and no change in tested heart, liver, kidney, thyroid or glucose markers. Two people and three days cannot show what is typical.
  • A 2021 retrospective chart review of 16 knee-injection patients collected outcomes by phone, without validated measures.
  • A registered phase 1 trial of oral tablets in healthy volunteers has no posted results.

Reported in animal studies

Preclinical safety studies, summarized in the 2025 HSS Journal review, reported no adverse effects across several organ systems in animals. That does not transfer to people: most studies tested a single dose level, most come from one research group, and animals cannot report many symptoms.

What is unknown

  • Effects of repeated use in people, over weeks or months.
  • Immune reactions: FDA flags possible immunogenicity for some routes, and complexities with peptide-related impurities.
  • Interactions with prescription drugs or supplements.
  • Effects in pregnancy, breastfeeding, children and teens.
  • Effects in people with cancer. Animal research describes BPC-157 as acting on blood-vessel growth (angiogenesis); how that applies to people with an existing tumor has not been studied.

Injection-site effects

Any injection can cause redness, swelling, tenderness, bruising or itching where the needle went in. Spreading redness, warmth, pus or fever can mean infection: contact your provider promptly. Trouble breathing, swelling of the face or throat, or a widespread rash: call 911.

Who should not use BPC-157 without talking to a provider first

  • Pregnant, trying to conceive or breastfeeding: there are no human data.
  • Under 18.
  • Active cancer or a history of cancer: tell your provider; this is a discussion point, given the angiogenesis research.
  • A known allergy to BPC-157 or any ingredient in the product.
  • Any other medications or supplements: tell your provider about all of them.
  • Competitive athletes: check your sport’s anti-doping rules; the 2025 systematic review advises counseling athletes on them.

What FDA has said about BPC-157

In 2023 FDA placed BPC-157 in Category 2 of its interim compounding lists (substances raising significant safety concerns). In April 2026 the nominations were withdrawn, and FDA’s page now lists BPC-157 under “nominated but withdrawn,” while keeping its concerns on record: possible immunogenicity, peptide-related impurities, and too little safety information to know whether it would cause harm in humans.

HHS’s October 2026 policy does not change that. HHS says it does not grant FDA approval or establish clinical safety and effectiveness.

Report a serious reaction

Report serious side effects to your prescriber and to FDA MedWatch, online or at 1-888-463-6332. Under the 2026 policy, compounders must report serious adverse events to MedWatch too.

FDA MedWatch

Is BPC-157 safe?

There is not enough human evidence to answer that. FDA says it lacks sufficient information to know whether BPC-157 would cause harm in humans, and a 2025 systematic review found no clinical safety data in people. Animal studies report few adverse effects, but they cannot settle the question. Talk to a licensed provider.

What are the side effects of BPC-157?

No human study has measured BPC-157 side effects systematically. A two-person IV pilot reported none over three days, and animal studies report few. Any injection can cause redness, swelling or bruising at the site. FDA flags possible immune reactions and impurities. Long-term effects in people are unknown.

Sources

  1. Vasireddi et al., HSS Journal 2025 — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (read November 2, 2026)
  2. Lee & Burgess, Altern Ther Health Med 2025 — Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (read November 2, 2026)
  3. Lee & Padgett, Altern Ther Health Med 2021 — Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (read November 2, 2026)
  4. ClinicalTrials.gov — NCT02637284, PCO-02 (BPC-157 oral tablets) Phase I safety and pharmacokinetics trial, status unknown (read November 2, 2026)
  5. Józwiak et al., Pharmaceuticals 2025 — Reply to Sikiric et al., comment on “Multifunctionality and Possible Medical Application of the BPC 157 Peptide” (read November 2, 2026)
  6. Seiwerth et al., Curr Pharm Des 2018 — BPC 157 and Standard Angiogenic Growth Factors (review) (read November 2, 2026)
  7. FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) (read November 2, 2026)
  8. Holland & Knight, Oct 16 2026 — Peptides at a crossroads: what wellness providers need to know (read November 2, 2026)
  9. AJMC (Steinzor), Oct 29 2026 — 5 things to know about HHS’s interim peptide compounding policy (read November 2, 2026)
  10. FDA — MedWatch: The FDA Safety Information and Adverse Event Reporting Program (read November 2, 2026)
  11. Foley & Lardner (Holtz, Beaver, Rosen), National Law Review, Oct 30 2026 — Peptides: HHS announces limited enforcement discretion for compounding six peptides (read November 2, 2026)

Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·